Semaglutide and kidney outcomes: read FLOW’s composite endpoint

A headline saying semaglutide reduced kidney risk can conceal which patients were studied and which events counted. FLOW provides important randomized evidence in people with type 2 diabetes and chronic kidney disease. Its result should remain attached to that population and to the trial’s complete outcome definition.

What counted as a primary event?

FLOW randomized 3,533 participants to subcutaneous semaglutide or placebo. The primary outcome combined kidney failure, a substantial decline in estimated filtration, and death from kidney-related or cardiovascular causes. During median follow-up of 3.4 years, there were 331 first primary events with semaglutide and 410 with placebo; the hazard ratio was 0.76. See the primary FLOW publication.

The often-quoted 24% reduction is a relative reduction in this composite outcome. It does not mean 24% of participants avoided dialysis, and it is not a 24-percentage-point absolute improvement. The outcome includes several kinds of events, so their individual results deserve separate attention.

Match the kidney disease definition

Eligibility used specified ranges of kidney filtration and urinary albumin. The study therefore does not establish the same effect for every kidney diagnosis or for people without diabetes. Someone with another form of kidney disease should ask which evidence actually matches it.

Bring the diagnosis and available kidney-function records to the clinician rather than assuming the word “kidney” makes all results transferable. The important question is whether FLOW’s population informs the person’s existing care plan.

Separate chronic benefit from treatment monitoring

A favorable long-term trial result does not mean kidney-related monitoring becomes unnecessary. The current Wegovy label, for example, includes an acute-kidney-injury warning related to volume depletion. Benefit in a defined disease setting and management of treatment-related risks are different clinical questions.

A consultation can address who reviews kidney results, how existing medicines fit together and what symptoms require contacting the care team. This article does not supply medication changes or a monitoring schedule.

Finally, FLOW studied a defined subcutaneous intervention. It does not validate an unrelated compounded preparation or oral formulation. Use its evidence to ask a more precise question about appropriate care, with the population, route and composite endpoint visible beside the headline.

Ask the clinician to distinguish the overall composite from kidney-only findings and to explain which outcome would matter most for your diagnosis. Keeping those questions separate makes the reported relative reduction easier to interpret.